TLSI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TLSI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of TriSalus Life Sciences is: No Data: Cannot be evaluated.
For the Medical Devices subindustry, TriSalus Life Sciences's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Risk Assessment distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's Risk Assessment falls into.
TriSalus Life Sciences (NAS:TLSI) Risk Assessment Explanation
Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Thank you for viewing the detailed overview of TriSalus Life Sciences's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Jodi Devlin | officer: President, Therapeutics | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
James Alecxih | officer: President, Device Technology | C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065 |
Bryan F. Cox | officer: Chief Scientific & Manufact. | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Kerry R Hicks | director | C/O HEALTHGRADES.COM, 44 UNION BLVD SUITE 600, LAKEOOD CO 80228 |
George Kelly Martin | director | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Jennifer Stevens | officer: Chief Regulatory Officer | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Richard Marshak | officer: Sr.VP, Corp. Dev. & Strategy | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Mary T Szela | director, officer: CEO and President | 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
Anil K. Singhal | director | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Sean Murphy | director, officer: Chief Financial Officer | C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703 |
Arjun Jj Desai | director | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Steven C Katz | officer: Chief Medical Officer | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Mats Wahlstrom | director, 10 percent owner | 500 GOLDEN RIDGE ROAD, SUITE 100, GOLDEN CO 80401 |
Von Eschenbach Andrew C. | director | C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807 |
Equity Ab Frankenius | 10 percent owner | BOX 984, BORAS V7 SE-501 10 |
From GuruFocus
By Business Wire • 08-10-2023
By Business Wire • 11-04-2023
By Business Wire • 11-07-2023
By Business Wire • 11-03-2023
By GuruFocus Research • 11-14-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.